Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
J Cardiovasc Pharmacol. 2021 Jun 1;77(6):805-813. doi: 10.1097/FJC.0000000000001010.
Levosimendan, a calcium sensitizer, exerts inotropic action through improving left ventricular ejection fraction. We noticed that only few clinical studies are published in which the effects of levosimendan on cardiac function are studied by echocardiography. When screening the literature (PubMed, Embase, and CENTRAL, from inception to August 2020), we found 29 randomized controlled trials on levosimendan containing echocardiographic data. We included those studies, describing a total of 574 heart failure patients, in our meta-analysis and extracted 14 ultrasonic parameters, pooling the effect estimates using a random-effect model. Our analysis of the diastolic parameters of the left ventricle shows that levosimendan reduce the early/late transmitral diastolic peak flow velocity ratio [standardized mean difference (SMD) -0.45 to 95% confidence interval (CI) (-0.87 to -0.03), P = 0.037] and E/e' (e': mitral annulus peak early diastolic wave velocity using tissue-doppler imaging) [SMD -0.59, 95% CI (-0.8 to -0.39), P < 0.001]. As it regards the systolic parameters of the right ventricle, levosimendan increased tricuspid annular plane systolic excursion [SMD 0.62, 95% CI (0.28 to 0.95), P < 0.001] and tricuspid annular peak systolic velocity [SMD 0.75, 95% CI (0.35 to 1.16), P < 0.001], and reduced systolic pulmonary artery pressure [SMD -1.02, 95% CI (-1.32, -0.73), P < 0.001]. As it regards the diastolic parameters of the right ventricle, levosimendan was associated with the decrease of Aa (peak late diastolic tricuspid annular velocity using tissue-doppler imaging) [SMD -0.38, 95% CI (-0.76 to 0), P = 0.047] and increase of Ea (peak early diastolic tricuspid annular velocity using tissue-doppler imaging) [SMD 1.03, 95% CI (0.63 to 1.42), P < 0.001] and Ea/Aa [SMD 0.86, 95% CI (0.18 to 1.54), P = 0.013]. We show that levosimendan is associated with an amelioration in the diastolic and systolic functions of both ventricles in heart failure patients.
左西孟旦是一种钙离子增敏剂,通过改善左心室射血分数发挥正性肌力作用。我们注意到,只有少数临床研究发表了使用超声心动图研究左西孟旦对心功能影响的文章。在筛选文献(PubMed、Embase 和 CENTRAL,从建立到 2020 年 8 月)时,我们发现了 29 项包含左西孟旦超声心动图数据的随机对照试验。我们将这些研究纳入了荟萃分析,共纳入了 574 例心力衰竭患者,并提取了 14 项超声参数,使用随机效应模型汇总效应估计值。我们对左心室舒张参数的分析表明,左西孟旦降低了二尖瓣舒张早期/晚期峰值血流速度比[标准化均数差(SMD)-0.45,95%置信区间(CI)(-0.87 至 -0.03),P=0.037]和 E/e'(e':组织多普勒成像测量的二尖瓣环舒张早期波速度)[SMD-0.59,95%CI(-0.8 至 -0.39),P<0.001]。关于右心室的收缩参数,左西孟旦增加了三尖瓣环平面收缩期位移[SMD 0.62,95%CI(0.28 至 0.95),P<0.001]和三尖瓣环收缩期峰值速度[SMD 0.75,95%CI(0.35 至 1.16),P<0.001],降低了收缩期肺动脉压[SMD-1.02,95%CI(-1.32 至 -0.73),P<0.001]。关于右心室的舒张参数,左西孟旦与 Aa(组织多普勒成像测量的二尖瓣环舒张晚期峰值速度)的降低[SMD-0.38,95%CI(-0.76 至 0),P=0.047]和 Ea(组织多普勒成像测量的二尖瓣环舒张早期峰值速度)的增加[SMD 1.03,95%CI(0.63 至 1.42),P<0.001]和 Ea/Aa[SMD 0.86,95%CI(0.18 至 1.54),P=0.013]有关。我们表明,左西孟旦可改善心力衰竭患者的左右心室舒张和收缩功能。